8-K current report · filed Aug 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) 8-K Current Report: August 4, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.1#2HRMY overview

Short answer

Harmony Biosciences Holdings, Inc. (HRMY) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.1#2 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.

Harmony Biosciences Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026
  • Press release issued August 4, 2026
  • Detailed financial results and management commentary in Exhibit 99.1

Item 7.01 · Regulation FD Disclosure

  • Investor presentation posted August 4, 2026, providing management’s latest messaging for investors and analysts
  • Exhibit 99.2 contains the substantive business, strategy and outlook disclosures
  • Presentation includes forward-looking statements subject to material execution and regulatory risks
  • Disclosure is furnished, not filed, limiting liability and automatic incorporation into future SEC filings

Item EX-99.1 · Exhibit EX-99.1

  • Q2 WAKIX revenue $261.3M, up 30% year over year; average patients rose 450 to 8,950
  • 2026 WAKIX revenue guidance reiterated at $1.0B-$1.04B, supporting continued commercial momentum
  • Net income $75.4M, or $1.28 diluted EPS, versus $39.8M and $0.68 in Q2 2025
  • Gross-margin pressure: cost of product sold reached 24.2% of revenue versus 19.0%, driven by Novitium royalties
  • BP-205 Phase 1 data showed approximately 25-hour half-life and no serious or severe adverse events; Phase 2 planned for mid-2027

Item EX-99.1#2 · Exhibit EX-99.1

  • Q2 net product revenue $261.3M, up 30% year over year, with 8,950 average WAKIX patients and 450 net additions
  • 2026 net revenue guidance reiterated at $1.00B-$1.04B, supporting continued WAKIX commercial momentum
  • Net income $75.4M, up 90%, while cash, equivalents and investments reached $962.5M
  • BP-205 Phase 1 data supported once-daily dosing potential, with no serious or severe treatment-emergent adverse events
  • Key catalysts ahead: BP-205 multiple Phase 2 trials in mid-2027, pitolisant GR PDUFA April 1, 2027, and EPX-100 topline data in 1H 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Harmony Biosciences Holdings, Inc. 8-K filings

Get the next HRMY 8-K as it lands

Follow HRMY for push alerts, or ask the research agent what this filing means.